Farms.com Home   Ag Industry News

Tennessee’s Campos Foods recalls products because of misbranding and undeclared allergens

Items were produced on December 2, 2014

The United States Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) announced that Campos Foods out of Caryville, Tennessee is recalling about 5,300 pounds in chicken products because of misbranding and undeclared allergens that can be harmful.

The items, produced on December 2, 2014 and being recalled are:

  • Variously weighted bulk boxes of 90 pieces of “ROCKIN’ ROASTED ROASTED CHICKEN DRUM & THIGH (With Back) Smoke Flavour Added”.
  • 16-lb bulk boxes with around 32 pieces of “ROCKIN’ ROASTED ROASTED CHICKEN QUARTERS Smoke Flavour Added”.

The items will have “P-2260T” inside the USDA mark of inspection and were shipped nationwide.

The recall is being classified as Class 1, meaning “there is a reasonable probability that the use of the product will cause serious, adverse health consequences or death.”

The issue was first discovered when they were notified by a supplier that an ingredient was recalled by the U.S. Food and Drug Administration (FDA). The FDA released the “Adams Flavors, Foods & Ingredients Issues Allergy Alert On Undeclared Peanut Protein In Cumin Products.”

Both FSIS and Campos Foods have no reported cases of illness.

 

 

 

 

Labels found on the products being recalled.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.